|
1000
Asia Pacific J Clin Nutr (1996) 5(3): 157-160
Asia Pacific J Clin Nutr (1996) 5(3): 157-160
Homocysteine
and cardiovascular diseases
Klaus Pietrzik MD and A Brönstrup MSc
Institute of Nutritional Science,
Department of Pathophysiology of Nutrition, University of Bonn, Germany
Elevated homocysteine blood concentrations have
been identified as an independent risk factor for the development
of atherosclerotic lesions. The metabolism of the amino acid homocysteine
in the human body involves the vitamins folic acid, B-12 and B-6
as essential cofactors and coenzymes, respectively. There is an
inverse relationship between the status of the relevant B-vitamins
and the homocysteine blood concentration. Supplementation of these
vitamins results in a significant reduction of the homocysteine
level. However, nutritive amounts seems to be sufficient to obtain
this reduction, even in the case of elevated homocysteine levels.
Key words: homocysteine, cardiovascular
disease
Homocysteine and cardiovascular diseases
Atherosclerotic diseases like coronary heart disease
(CHD) and stroke are still the leading causes of death in the Western
World. A variety of risk factors have been associated with the development
of atherosclerotic diseases. Among them are hypertension, , hyperlipidaemia
and smoking , which together account for about 50% of the cases of
CHD. However, there must be additional reasons for CHD, since half
of the cases cannot be explained by the presence of the established
risk factors.
For several years, the amino acid homocysteine has
been considered as a potential risk factor for the development of
atherosclerotic diseases. The discovery of homocystinuria in 1962
drew first attention to the association between elevated homocysteine
blood levels and the occurrence of vascular diseases. In this inherited
metabolic disorder , homocysteine accumulates in the blood. This leads
to partial oxidation of homocysteine to homocysteine, which is then
excreted via the urine. If untreated, affected individuals develop
large atherosclerotic lesions as well as thromboembolic events early
in life and often die before the age of 30 from stroke or myocardial
infarction.
Metabolism of homocysteine
Homocysteine is exclusively derived from the
essential amino acid methionine and not taken from the diet.
Homocysteine can be remethylated to methionine or catabolised
to cysteine. Three vitamins of the B-group are involved in the
metabolism of homocysteine: folic acid as 5-methyl-tetrahydrofolic
acid (5-methyl-THF) is the donor of the methyl group required
for the remethylation reaction; Vitamin B-12 functions as coenzyme
in this reaction; T 1000 he formation of cysteine requires 2
enzymes for which vitamin B-6 in the form of 5-pyridoxal-phosphate
(PLP) serves as coenzyme (Fig. 1).
|
Figure 1. Metabolism of homocysteine
|
Relevance of homocysteine for the development of
atherosclerosis
Homocysteine as a risk factor for vascular diseases
From observations of extended and early-onset vascular
lesions in homocystinuric patients, the question arose whether homocysteine
levels, as seen in the general population, would be associated with
the development of atherosclerosis. Subsequently, several studies
examined the association between (moderately) elevated homocysteine
levels and the risk for atherosclerosis. In case-control studies,
a high percentage of patients with CHD showed elevated homocysteine
levels. Clarke et al1 found high homocysteine levels in
42% of patients with cerebrovascular diseases, 28% of patients with
peripheral vascular diseases and 30% of cases with coronary vascular
diseases. However, none of the healthy control persons showed an elevation
of homocysteine blood concentration. Others found that the mean homocysteine
level of patients with coronary, peripheral and cerebrovascular diseases
was significantly higher than that of comparable controls2-9.
Despite differences in study design, there is a striking
agreement between the numerous studies on this topic. So far, there
are 38 studies investigating the association of elevated homocysteine
levels and risk for atherosclerotic diseases. Of these 38 studies,
34 found such an association10. It was also shown that
elevated homocysteine levels are an independent risk factor
for the development of atherosclerotic diseases1,7,9,11,12.
In other words, even in the absence of other, established risk factors
like hypertension, smoking or hypercholesterolaemia, an increase in
homocysteine concentration alone can be responsible for the development
of atherosclerosis.
There seems to be a graded increment in the risk of
atherosclerosis with increasing homocysteine levels. It is now accepted
that a threshold, indicating a significantly elevated risk for persons
with homocysteine concentrations above that value, does not exist.
Calculations show that the risk for coronary disease is elevated by
60% for men and 80% for women with every 5 µmol/l increase in homocysteine
levels10.
Upon comparison of data on the relevance of various
risk factors it becomes evident that homocysteine plays an important
role as risk factor for atherosclerotic diseases1,10. It
is thought to be at least equally important as elevated cholesterol
levels10.
Vitamin supplementation as a means to influence
homocysteine levels
The metabolism and degradation of homocysteine in
the body requires the presence of the vitamins folic acid, vitamin
B-12 and vitamin B-6. A low status of these vitamins is rapidly reflected
by an increase in the homocysteine blood level. Therefore, homocysteine
can be referred to as a functional parameter of the vitamin nutritional
status of the respective B-vitamins. Seventy-seven of 78 patients
with vitamin B-12 -deficiency and 18 of 19 patients with confirmed
deficiency of folic acid had elevated homocysteine levels compared
to a healthy control group13. There exists an inverse relationship
between homocysteine and the relevant B-vitamins (Fig. 2): whereas
a low homocysteine level is associated with high blood concentrations
of folic acid and vitamin B-12, respectively, the homocyst 1000 eine
blood concentration increases with decreasing vitamin levels14.
Figure 2.
Relationship between homocysteine level and concentrations of
cobalamin and folate in serum (modified from [14]). |
|
Effectiveness
of vitamins to lower homocysteine levels
By supplementing the vitamins involved in the metabolism of homocysteine,
the blood level of this atherogenic amino acid can be lowered.
A combination of folic acid, vitamin B-12 and B-6 given daily
in an amount 2.5-4 times the RDA was able to lower the homocysteine
level significantly by 17-50%15,16. The extent depends
on the homocysteine concentration at the onset of supplementation:
the higher the level, the greater the observed treatment effect.
In our own studies, we were able to show that
the homocysteine level could be influenced with low (nutritive)
doses of the relevant vitamins even in the case of so-called
"normal" homocysteine concentrations and adequate
vitamin status prior to supplementation. In one of our studies,
72 female students were supplemented with a multivitamin tablet
containing 400µg folic acid, 2mg vitamin B-6 and 6µg vitamin
B-12 daily. Within four weeks, the mean homocysteine level decreased
significantly by as much as 21% (Fig. 3). Ongoing supplementation
did not lead to a further reduction.
Folic acid, vitamin B-12 and vitamin B-6 differ
in their potential to influence the homocysteine level. Vitamin
B-6 alone does not seem to have a lowering effect10,15.
Supplementing men with elevated homocysteine blood concentrations
with vitamin B-12 resulted in a decrease by 15%16.
However, in the respective study as much as 400 µg vitamin B-12
was given, which is about 133 times the daily requirement for
healthy adults. Folic acid seems to play the key role in lowering
homocysteine. In men, the reduction obtained by supplementing
folic acid alone did not differ significantly from the effect
obtained by giving a combination of folic acid, vitamin B-12
and vitamin B-6 (Fig. 4)16. Supplementation of folic
acid to young women was as effective in reducing the homocysteine
level as a combination of folic acid and vitamin B-615.
|
Figure 3. Influence of vitamin
supplementation on homocysteine levels in young women (n = 72)
|
Figure 4.
Response of homocysteine blood levels to different vitamin supplements
in men with elevated homocysteine levels. A significant reduction
of homocysteine was seen after supplementation with vitamin B-12
(0.4mg; p<0.01), folic acid (0.65mg; p<0.001) and the combination
(10mg Vitamin B-6, 0.4mg Vitamin B-12, 0.65mg Folsäure; p<0.001)
(modified from [16]) |
|
In their meta-analysis,
Boushey et al10 estimated that an increase in folic
acid intake could prevent up to 50 000 deaths per year due to
CHD in the USA. Calculations for Germany show that the death rate
from CHD could be reduced by up to 15 000 depending on the intervention
strategy used for increasing the uptake of folic acid (Table 1).
The key role of folic acid in lowering homocysteine
is also supported by other authors10,12,16 and can
be explained biochemically: In the metabolism of homocysteine,
vitamins B-6 and B-12 serve as co-enzymes and thus are not used
up during the reaction in which they are involved. Folic acid,
however, functions as donor of the methyl group in the remethylation
reaction and is used up quantitatively so that it has to be
regenerated to 5-methyl-THF. During the remethylation reaction,
the methyl group of 5-methyl-THF is transferred to vitamin B-12
and after that to homocysteine to form methionine. Therefore,
folic acid acts as limiting factor for this reaction and the
absence of the methyl donor cannot be compensated by vitamin
B-12. Vitamin B-12 does not seem to play a key role because
it is usually present in sufficient amounts due to large stores
of this B-vitamin in the body.
The minor role of vitamin B-6 is thought to
result from the possibility of the body to increase the remethylation
rate in the case of a lack of the respective coenzyme (PLP)
and thus limited degradation of homocysteine to cysteine via
the transsulfuration pathway. This increase in the remethylation
rate seems sufficient to prevent an accumulation of homocysteine
in the body17.
|
Table 1. Potential reduction
of deaths from coronary heart disease (CHD) for persons aged 45
years and older based on different intervention strategies.
Intervention
strategy |
Annual number of potentially
preventable deaths
|
|
USA
|
Germany
|
Food fortification
(flour and cereal products)
|
up to 50 000*
|
15 000**
|
Folic acid supplements
(assuming high effectiveness)
|
1000
up to 28 000*
|
10 000**
|
Nutrition education
(assuming high effectiveness)
|
up to 26 500*
|
8 000**
|
* Data for USA from JAMA 1995; 274: 1049 - 1057.
** Data calculated for Germany (Pietrzik 1995).
|
So far it is known that nutritive amounts of folic
acid are able to lower homocysteine levels in young women. This age
group usually has homocysteine levels below 10µmol/l. "Normal"
levels have not been defined yet. The homocysteine blood concentration
increases with age and reaches levels of 10-15µmol/l in healthy adults
of middle age. Elderly persons show homocysteine concentrations of
about 10-25µmol/l. We assume that nutritive amounts are still sufficient
to effectively lower these levels and are currently investigating
this topic. However, it might be possible that elderly people require
a combination of all vitamins involved in the metabolism of homocysteine
since they often have a suboptimal vitamin status. Data from the Framingham
study show that 30% of the patients had an elevated homocysteine level.
In 67% of these patients a suboptimal vitamin status of one or more
of the three B-vitamins was found and thought to be the cause for
the elevation of homocysteine18. It is also known that
about 30% of elderly people have an atrophic gastritis which may lower
the absorption of vitamin B-12 and lead to a suboptimal status of
this vitamin over time.
Homocysteine and cardiovascular
diseases
Klaus Pietrzik and A Brönstrup
Asia Pacific Journal of Clinical
Nutrition (1996) Volume 5, Number 3: 157-160
References
- Clarke R, Daly L, Robinson K, Naughten E, Cahalane
S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk
factor for vascular disease. N Engl J Med 1991; 324: 1149-1155.
- Arnesen E, Refsum H, Bųnaa KH, Ueland PM, Fųrde
OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease.
Int J Epidemiol 1995; 24: 704-709.
- Brattström LE, Lindgren A, Israelsson B, Malinow
MR, Norrving B, Upson B. Hyperhomocysteinemia in stroke: prevalence,
cause and relationships to type of stroke and stroke risk factors.
Eur J Clin Invest 1992; 22: 214-221.
- Genest JJ, McNamara JR, Salem DN, Wilson PWF, Schaefer
EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature
coronary artery disease. J Am Coll Cardiol 1990; 16: 1114-1119.
- Israelsson B, Brattström LE, Hultberg BL. Homocysteine
and myocardial infarction. Atherosclerosis 1988; 71: 227-233.
- f5f Malinow MR, Sexton G, Averbuch M, Grosman
M, Wilson D, Upson B. Homocyst(e)inemia in daily practice. Coron
Artery Dis 1990; 1: 215-220.
- Mölgaard J, Malinow MR, Lassvik C, Holm A-C Upsin
B, Olsson AG. Hyperhomocyt(e)inemia: an independent risk factor
for intermittent claudication. J Intern Med 1992; 231: 273-279.
- Pancharuniti N, Lewis CA, Sauberlich HE, Perkins
LL, Go RCP, Alvarez JO, Macaluso M, Acton RT, Copeland RB, Cousins
AL, Gore TB, Cornwell PE, Roseman JM. Plasma homocyst(e)ine, folate,
and vitamin B-12 concentrations and risk for early-onset coronary
artery disease. Am J Clin Nutr 1994; 59: 940-948.
- Stampfer MJ, Malinow MR, Willett WC, Newcomer LM,
Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study
of plasma homocyst(e)ine and risk of myocardial infarction in US
physicians. JAMA 1992; 268: 877-881.
- Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG.
A quantitative assessment of plasma homocysteine as a risk factor
for vascular disease. JAMA 1995; 274: 1049-1057.
- Coull BM, Malinow MR, Beamer N, Sexton G, Nordt
F, deGarmo P. Elevated plasma homocyst(e)ine concentration as a
possible independent risk factor for stroke. Stroke 1990; 21: 572-576.
- Hopkins PN, Wu LL, Wu J, Hunt SC, James BC, Vincent
GM, Williams RR. Higher plasma homocyst(e)ine and increased susceptibility
to adverse effects of low folate in early familial coronary artery
disease. Arterioscler Thromb Vasc Biol 1995; 15: 1314-1320.
- Stabler SP, Marcell PD, Podell ER, Allen RH, Savage
DG, Lindenbaum J. Elevation of total homocysteine in the serum of
patients with cobalamin or folate deficiency detected by capillary
gas chromoatography-mass spectrometry. J Clin Invest 1988; 81: 466-474.
- Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson
A, Allen RH. Total homocysteine in plasma or serum: methods and
clinical applications. Clin Chem 1993; 39: 1764-1779.
- Dierkes J. Vitamin requirements for the reduction
of homocysteine blood levels in healthy young women. PhD-thesis:
Faculty of Agriculture, University of Bonn, 1994.
- Ubbink JB, Vermaak WJH, van der Merwe A, Becker
PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment
of hyperhomocysteinemia in humans. J Nutr 1994; 124: 1927-1933.
- Miller JW, Nadeau MR, Smith D, Selhub J. Vitamin
B-6 deficiency vs folate deficiency: comparison of responses to
methionine loading in rats. Am J Clin Nutr 1994; 59: 1033-1039.
- Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg
IH. Vitamin status and intake as primary determinants of homocysteinemia
in an elderly population. JAMA 1993; 270: 2693-2698.
Copyright © 1996 [Asia Pacific Journal of Clinical Nutrition]. All
rights reserved.
Revised:
January 19, 1999
.
to the top
0
|